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Abstract 
 
The Effects of Dihydrobiopterin and Tetrahydrobiopterin on Hydrogen Peroxide and 
Nitric Oxide Release during Extracorporeal Shockwave Lithotripsy (ESWL) 
 
ESWL is an effective, non-invasive therapy utilized to fragment stones in the 
kidney and subsequently be cleared in the urinary tract. Although lithotripsy provides a 
safer alternative to invasive treatments for removing stones, ESWL may cause 
vasoconstriction after ESWL treatment, reducing renal blood flow, which can cause 
kidney damage leading to acute to chronic hypertension clinically. This may be due to 
kidney vascular endothelial dysfunction, which is characterized as increased oxidative 
stress and decreased endothelial nitric oxide synthase (eNOS)-derived nitric oxide (NO) 
bioavailability. We hypothesized that ESWL would decrease NO and increase hydrogen 
peroxide (H2O2) in rat renal veins. Rats given tetrahydrobiopterin (BH4), the essential 
cofactor of eNOS coupling, would cause a decrease in H2O2 release and increase in NO 
release compared to ESWL + saline controls. On the contrary, when dihydrobiopterin 
(BH2), the cofactor for eNOS uncoupling, is given at the end of ESWL treatment we 
predict an increase in H2O2 release and decrease in NO release compared to ESWL + 
saline controls. Blood NO and H2O2 were directly measured in real-time by inserting a 
microsensor into the left renal vein in the anesthetized rat.  ESWL treatment consisted of 
1,000 shocks for approximately 13 minutes.  Saline or drug was injected via the jugular 
vein immediately post-ESWL and at the same time point for the non-ESWL controls. 
ESWL + saline controls (n = 5; p< 0.01) had significantly increased H2O2 release 
compared to the non-ESWL controls (n = 5) and NO release in ESWL + saline rats (n = 
5; p< 0.01) was significantly decreased compared to non-ESWL controls (n = 6) from 5-
 	   v	  
30 mins post-ESWL. In ESWL+BH4 rats (n=5), H2O2 released was significantly reduced 
from 10-30 mins compared to ESWL + saline controls (p≤ 0.05). ESWL+BH4 (n=5) also 
significantly increased NO release 5-30 mins compared to ESWL + saline controls (p≤ 
0.01). For both NO (n=5) and H2O2 (n=5) release, the ESWL + BH2 group showed a 
similar decrease in NO and increase in H2O2 release to the ESWL + saline group (n=5).  
This may be because eNOS could be under saturated conditions with respect to BH2 
levels generated by ESWL. The data shows that BH4 significantly reduces H2O2 and 
increases NO, thereby promoting eNOS coupling.  This results in increased NO 
bioavailability and decreased oxidative stress on the renal microvasculature. 
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Introduction 
 
 The kidneys are essential organs in the human body for maintaining homeostasis 
by regulating blood pressure, maintaining pH and filtering toxic by-products from the 
blood.  Urinary calculi, or stones located in the kidney or ureter, can pose potentially life-
threatening problems and urologists are faced with the issue of how to effectively and 
safely remove these kidney stones.  Extracorporeal shock wave therapy (ESWL) is an 
effective, non-invasive, clinical treatment for kidney stones.  ESWL treatment is used to 
fragment stones located in the kidney or ureter.  ESWL is the treatment of choice for 
many urologists because of its low morbidity, high success rate and less-invasive nature 
as compared to an invasive surgical approach (You et al. 2010; Childs et al. 2011).  A 
lithotripter breaks down kidney stones by focusing high-intensity, acoustic pulses through 
a lens and propagates these shockwaves in the area of the stone, in turn breaking up the 
stone.  After treatment, the fragmented pieces, which are less that 1mm in diameter, are 
passed with the flow of the urinary tract.   
Although lithotripsy provides a safer treatment option for removing the harmful 
stones, the problem that arises is that to break up the kidney stone, it requires many 
repetitive shockwaves that not only hit the kidney stone but also hit the surrounding renal 
tissue.  These forces used to fragment the stone can cause underlying damage to the renal 
vascular endothelium, which may not be easily detected.  Furthermore, ESWL not only 
causes damage by the physical forces of the shockwaves, but also through increased 
oxidative stress indirectly from the shockwaves.  ESWL may cause prolonged 
vasoconstriction after ESWL treatment, reducing renal blood flow, increasing leukocyte-
endothelial interactions, and subsequent endothelial dysfunction, which may cause 
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kidney damage leading to acute to chronic hypertension clinically.  A 19-year follow-up 
ESWL study showed that a subpopulation developed hypertension (Krambeck et al. 
2006).  There is a lack of research examining the pharmacotherapeutics that can be used 
to treat this endothelial dysfunction caused by ESWL.  As a result, this current study 
investigates how this endothelial dysfunction can be decreased which may regain normal 
kidney function by using pharmacological therapy to reduce the release of superoxide 
(SO) and subsequent hydrogen peroxide (H2O2) release in blood by promoting 
endothelial nitric oxide synthase (eNOS) coupling with tetrahydrobiopterin (BH4). 
 
ESWL Treatment: Limitations and Improvements 
 
 In the past three decades, there has been significant evolution in the clinical 
management of kidney stones, and the trend has gone away from surgical treatment 
options to minimally invasive procedures, such as shockwave lithotripsy (Childs et al. 
2011).  Since the introduction of lithotripsy in the 1980s, it has been regarded as the 
primary treatment option for the treatment of kidney stones, but this does not mean that it 
does not come without its limitations (Gillitzer et al. 2009).  One of the limitations of 
shockwave lithotripsy is the size and composition of the kidney stone.  Taking into 
account the capacity of the kidney and ureter to clear debris, shockwave treatment is only 
recommended for kidney stones that are smaller that 1-2 cm.  Furthermore, shockwave 
treatment is not recommended in cases of kidney stones with unfavorable composition, 
such as cysteine, brushite and calcium oxalate monohydrate (Childs et al. 2001; Gillitzer 
et al. 2009).  Other factors besides stone size and composition that are shown to affect 
stone fragmentation by lithotripsy are the location of the stone, the stone’s radiodensity, 
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the patient’s body mass index, and the degree of hydronephrosis, or swelling due to 
increased water inside the kidney (You et al. 2010). 
Kidney stones treated with shockwave lithotripsy are mainly comminuted, or 
broken up, by two mechanisms.  The first force is from a positive pressure wave, where 
the actual shockwave, or stress wave, acts in a hammer-like action to cause stone 
fragmentation at both ends of the stone.  The second force is from cavitation, where 
negative pressure waves cause the expansion and collapse of cavitation bubbles in the 
fluid surrounding the stone (Rassweiler et al. 2011).  Stress waves and cavitation bubbles 
have shown to work in a synergistic manner to accomplish stone fragmentation.  Stress 
waves initiate the fragmentation at low output voltages, but higher-energy shockwaves 
are needed to create the cavitation bubbles and to overcome the scattering effect 
(Maloney et al. 2006).  The scattering effect in lithotripsy is where fine fragments gather 
around the remaining stone and scatter the subsequent shockwaves, and this is overcome 
by increasing the shockwave intensity, which maintains the stone fragmentation (You et 
al. 2010).  In order to maximize the efficiency of shockwave lithotripsy, you need the 
optimal combination of the intensity, number and rate of shockwaves that causes the least 
amount of tissue injury while also causing the most stone fragmentation, all while using a 
minimal amount of energy.  If other factors remain constant, the degree of stone 
fragmentation increases proportionally to the number and intensity of shockwaves, but 
unfortunately, the degree of renal tissue injury also increases proportionally to the 
shockwave dose and rate (You et al. 2010). 
  Although shockwave lithotripsy is regarded as the first-line option and most 
commonly performed procedure for stone treatment, especially those stones located in the 
   4 	  
upper urinary tract, it does cause acute injury that has been reported to lead to long-term 
complications (McAteer and Evan 2008).  Research has shown that ESWL causes acute 
renal injury in most patients who receive a large enough shockwave dose to break-up the 
kidney stone.  This renal injury is mostly vasculature injury whereby the shockwaves 
caused lesions and ruptured blood vessels in the kidney, which can cause hemorrhage 
into the renal tissue.  Moreover, if severe enough, this parenchymal bleeding can cause 
subcapsular hematomas or even lead to renal failure in some cases (Connors et al. 2009).  
Studies have shown that vascular lesion size and the volume of hemorraghic tissue in the 
kidney increases proportionally to the number of shockwaves given and the shockwave 
intensity (McAteer and Evan 2008).  Furthermore, cavitation bubbles are also believed to 
play a role in the vascular injury that occurs from ESWL treatment.  When cavitation 
bubbles collapse, they create a fluid micro-jet that delivers a significant force to a small 
area.  If one of these cavitation bubbles were to expand and collapse inside of a blood 
vessel, the force of the generated micro-jet would possibly be able to rupture the blood 
vessel (McAteer and Evan 2008). 
These acute injuries to the renal vasculature from shockwave lithotripsy, although 
not directly proven to be the definite cause of chronic hypertensive disease, have been of 
serious concern to lead to long-term complications.  Possible chronic complications from 
ESWL, especially in patients that have received multiple lithotripsy treatments, include 
new-onset hypertension, diabetes mellitus, and the exacerbation of stone disease 
(McAteer and Evan et al. 2008).   
Ongoing research has examined the ESWL protocol to determine parameters that 
set the highest efficacy while making patient safety the main concern.  In order to 
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determine the safest and most efficient protocol, researchers have investigated ESWL 
factors including the number of shockwaves, the frequency of the shockwaves delivered, 
the voltage output of the lithotripter, step-wise treatment versus constant energy output, 
and pretreatment shockwaves.  Ultimately, the goal is to completely break up the kidney 
stone so that it can be passed through the urinary tract, all while causing the least amount 
of renal damage by delivering the least amount of shockwaves with the lowest energy 
output at the lowest rate of administration.   
The results of the ongoing research have yielded many beneficial changes to the 
standard ESWL protocol.  One study using animal models has shown that ESWL damage 
to the kidney is dose-dependent.  The damage to the kidney increased with the number of 
shockwaves delivered, and the high-amplitude shockwaves proved to be more damaging 
than the lower-amplitude shockwaves (Patterson et al. 2002).  Furthermore, the findings 
of this study have shown that trauma to the kidney from ESWL treatment is significantly 
reduced at a slow rate of shockwave administration (30 shockwaves/min), and that it also 
significantly increased stone comminution compared to the conventional ESWL rate of 
delivery (120 shockwaves/min) (Patterson et al. 2002).  A second study showed that 
while delivering shockwaves at a rate of 30 shockwaves per minute may be time-
consuming and unrealistic in a clinical setting.  A comparison of shockwave frequencies 
of 60 shockwaves per minute versus 120 shockwaves per minute still showed improved 
stone comminution at 60 shockwaves per minute, which would provide a more realistic 
clinical alternative (Gillitzer et al. 2008).  Knowing the improved stone comminution at 
60 shockwaves per minute and how it is a more realistic clinical treatment option than 
delivering at a rate of 30 shockwaves per minute, a third study assessed the renal 
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response to treating with ESWL at a rate of 60 shockwaves per minute.  The results from 
this study showed significantly reduced size of the acute hemorrhagic lesion in the 
kidneys treated at a rate of 60 shockwaves per minute compared to those treated at 120 
shockwaves per minute (Connors et al. 2009). 
In addition to studies on ESWL frequency, there has been ongoing research 
investigating the effect of output voltage distribution on stone comminution efficiency.  
Two studies have both proven that a progressive increase in lithotripter output voltage 
generates the greatest stone comminution efficiency compared to a constant or decreasing 
output voltage during ESWL treatment (You et al. 2010; Maloney et al. 2006).  The 
mechanism behind the efficiency of increased voltage output is that in the beginning of 
ESWL the stress waves initiate stone fragmentation at low output voltages.  In the later 
part of ESWL therapy, the higher output voltages will increase cavitation activity and 
also overcome the scattering effect caused by the collection of fine stone particles 
surrounding the remaining kidney stone (Maloney et al. 2006). 
Lastly, one study has shown that “pretreatment” with shockwaves at a low energy 
output can protect the kidney from injury from subsequent higher energy shockwaves.  
The study proved that pretreatment with as little as 100 shockwaves at 12 kilovolts (kV) 
prior to treatment of 2,000 shockwaves at 24 kV on the same area significantly reduced 
the size of the lesion.  Although the mechanism for this protective effect from 
pretreatment is not fully understood, an analysis of renal hemodynamics in this study 
have shown that shockwaves produce transient vasoconstriction in the kidney, and this 
increased vascular tone during pretreatment may make the vessels less susceptible to 
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damage, such as vessel rupture, during the subsequent high energy shockwaves (McAteer 
and Evan 2008). 
Using these studies, researchers were able to develop a new ESWL treatment 
protocol that generates more effective stone comminution with less injury to the kidney 
itself.  This new protocol called for a slower rate of shockwave administration with 60 
shockwaves per minute instead of 120 shockwaves per minute, using as little shockwaves 
as necessary with a progressively increasing energy output from 12 kilovolts (kV) as the 
priming dosage to 24 kV during the ESWL treatment (McAteer and Evan 2008).  
However, despite the adopted changes to the ESWL protocol that yields significantly 
reduced injury to the kidney, our lab has produced research showing that oxidative stress 
is increased post-ESWL treatment.  Our recent study has shown that ESWL generates 
increases in H2O2 and decreases in NO release levels similar to an ischemia-reperfusion  
(I/R) injury and characteristic of eNOS dysfunction.  Although ESWL treatment is not a 
true representation of an I/R event where a complete loss of blood perfusion occurs 
during ischemia, oxidative stress occurs as a result of ESWL.  ESWL shockwaves cause 
localized areas of tissue ischemia in the kidney, which are susceptible to free radical 
generation during reperfusion, when ESWL treatment is ceased and blood flow is 
restored to these areas.  Our ESWL protocol is similar to one used by Weber et al (1992) 
in rats that consists of 1000 shockwaves total.  The first 500 shockwaves are delivered at 
a rate of 60 shockwaves/minute followed by 500 shockwaves at 120 shockwaves/minute 
(Weber et al. 1992).  Other studies suggest that ESWL induces oxidative stress and 
decreased NO bioavailability.  
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This increase in oxidative stress post-ESWL has led our lab to investigate the role 
of eNOS during oxidative stress caused by ESWL treatment, and we aimed to decrease 
this oxidative stress by manipulating eNOS regulation pharmacotherapeutically.  
Hopefully, treatment of the oxidative stress to the renal vasculature endothelium will be 
crucial to diminish or prevent the acute injuries that occur during ESWL treatment 
leading to long-term complications in the kidney. 
 
Endothelium and Nitric Oxide 
 Vascular endothelium is the layer of cells that lines the entire circulatory system, 
and creates a crucial barrier between the circulating blood and the vessel wall.  The 
endothelium is important since it provides a physical barrier between blood and tissue 
and maintains vascular homeostasis.  The endothelial cells form a semi-permeable barrier 
between the blood vessel lumen and the surrounding tissue, and they are able to control 
the transfer of molecules into and out of the circulating bloodstream.  The endothelium 
also plays a role in blood clotting, as it provides an anti-thrombotic surface, but 
inflammation can initiate when it becomes dysfunctional.  Furthermore, the vascular 
endothelium is able to control blood pressure by regulating vasoconstriction and 
vasodilatation.  The endothelial cells can release vasodilators, such as nitric oxide (NO), 
which serves as a primary vasodilator and causes smooth muscle relaxation.  In addition 
to vasodilatation and smooth muscle relaxation, NO is a critical regulator of multiple 
aspects of homeostasis in the cardiovascular system, including blood pressure, 
inflammation and platelet activation (Channon 2004).   Furthermore, NO is a pivotal 
molecule in the regulation of blood flow and tissue oxygenation, and NO affects oxygen 
supply and demand in two ways.  The first aspect is that NO regulates vascular tone and 
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blood flow by activating soluble guanylate cyclase in the vascular smooth muscle, and 
the second aspect is that it controls mitochondrial oxygen consumption by inhibiting 
cytochrome c oxidase (Chen et al. 2008). The loss of NO bioavailability from the 
vascular endothelium is a major characteristic of endothelial dysfunction, which causes 
various vascular diseases including hypertension, diabetes and atherosclerosis (Channon 
2004).  An impaired endothelial-dependent vasorelaxation is seen in these disease states, 
and this is associated with an increased oxidative vascular damage.  Research has 
proposed that alteration in the levels of both nitric oxide and superoxide are responsible 
for endothelial dysfunction that leads to these vascular diseases (Vasquez-Vivar et al. 
1998). 
 
The Structure and Function of eNOS 
 eNOS is the primary producer of NO in the vascular endothelium that lines the 
cardiovascular system.  NO produced from eNOS in the vascular endothelium is known 
to be the key source of NO for regulating vasorelaxation.  eNOS, also known as NOS3, is 
one of three isoforms of nitric oxide synthase (NOS) that have been identified, and the 
other two isoforms are neuronal NOS (nNOS) and inducible NOS (iNOS).  Both eNOS 
and nNOS are constitutively expressed and controlled by the availability of intracellular 
calcium and calmodulin, whereas iNOS is upregulated principally in leukocytes in 
chronic disease states and releases micromolar amounts of NO (Chen et al. 2008; 
Vasquez-Vivar et al. 2003). 
 eNOS is primarily located within caveolae located on the endothelium surface.  
This enzyme consists of two identical monomer units, and they consist of a flavin-
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containing reductase domain and a heme-containing oxygenase domain, which contains a 
prosthetic heme group and a binding site for BH4 and dihydrobiopterin (BH2) molecules, 
and they are connected together by a calcium/calmodulin binding peptide.  Upon the 
calcium/calmodulin binding, electrons from NADPH are transferred from the reductase 
domain to the oxygenase domain, whereby eNOS becomes activated (Vasquez-Vivar et 
al. 2003).  eNOS is a cytochrome p450 reductase-like enzyme that catalyzes the electron 
flow from NADPH through the flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN) and then transferred to the oxidase domain of the other monomer 
to a prosthetic heme group, where the oxidation of L-arginine occurs (Cai and Harrison 
2000). 
 An important aspect of proper eNOS function is the necessity of the BH4 cofactor.  
BH4 binds on the oxygenase domain adjacent to the heme active site.  There is one 
binding site for BH4 on the oxygenase domain of each monomer, so in total there are two 
BH4 molecules on each eNOS homodimer (Alp and Channon 2004).  The location at 
which the BH4 cofactor binds at the interface between the two monomers is important to 
maintain the functional configuration of the enzyme because it provides stability of the 
homodimer through numerous hydrogen bonds.  Along with the stabilization of the eNOS 
dimer, BH4 is also a major component in the oxidation of L-arginine to its intermediate 
N-hydroxyl-L-arginine followed by the oxidation of the intermediate to produce NO and 
L-citrulline (Raman et al. 1998).  This entire reaction depends on the electron flow from 
NADPH to FAD to FMN and lastly to the oxygen molecule, located on heme-iron group 
forming a ferrous-dioxygen complex. 
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eNOS Coupling and Uncoupling 
 
 It has been well established that under normal conditions endothelial-derived NO 
is produced from eNOS when BH4 is the cofactor, and this process is referred to as eNOS 
coupling.  In the coupled state with BH4 as the cofactor, the electron flow is generated 
through NADPH to FAD to FMN to the oxygenase domain, and this is “coupled” with 
the oxidation of the guanadino nitrogen of L-arginine in the presence of molecular 
oxygen to produce L-citrulline and NO.  (See Figure 1a) The BH4 cofactor is needed to 
aid in the coupling of the L-arginine substrate and the heme site of the eNOS oxygenase 
domain (Chen et al. 2010).  By contrast, when the electron transfer within the active site 
becomes “uncoupled” from L-arginine oxidation, eNOS uses the molecular oxygen as a 
substrate to generate SO instead of NO (Chen et al. 2010). (See Figure 1b)  This process 
is known as eNOS uncoupling and occurs when BH2 is the predominant cofactor.  
Subsequently, SO is further converted to hydrogen peroxide (H2O2) by superoxide 
dismutase (SOD) (Perkins et al. 2012).  It is well known that H2O2 is a good indicator or 
oxidative stress, and it has a longer half-life (i.e. minutes) compared to SO (i.e. seconds), 
which makes it easier to measure (Chen et al. 2010).  BH4 and BH2 bind to eNOS with 
equal affinity, therefore the relative ratio between these two cofactors determines the 
principal product from eNOS. 
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Figure 1. Schematic Diagram of eNOS Coupling and Uncoupling. 
When BH4 is the eNOS cofactor, it binds to the heme oxygenase domain to promote 
the binding of the L-arginine substrate.  (Left of figure) In the coupled state, the 
electron flow is “coupled” to the oxidation of L-arginine in the presence of 
molecular oxygen to produce L-citrulline and NO.  (Right of figure) By contrast 
when BH4 is oxidized to BH2 or when the BH2/BH4 ratio is increased, the process 
becomes uncoupled and L-arginine does not bind to eNOS and uncoupled oxygen 
accepts the electron to produce superoxide. Adopted from Chen et al. 2010. 
 
BH4 is susceptible to oxidation by reactive oxygen species to form BH2. There are 
several mechanisms that produce reactive oxygen species but the main sources that 
produce SO are NADPH oxidases, mitochondrial respiration, and uncoupled eNOS. 
NADPH oxidases are upregulated in certain cardiovascular risk factors such as 
hypertension or in conditions of exacerbated oxidative stress.  (Bertolet et al. 2013).  
Additional oxidation of BH4 can come from incomplete oxidative phosphorylation in 
mitochondria dysfunction.  The mitochondrial electron transport chain is the predominant 
source of SO in cells going through normal respiration, and a SO molecule is needed for 
the initial oxidation of BH4 to BH2.  The Crabtree et al (2008) study concluded that 
mitochondrion-derived SO plays a role in BH4 oxidation, by showing that BH4 oxidation 
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was significantly decreased by selective inhibitors of mitochondrial electron transport 
complexes I or II.  Their findings implicate a role for mitochondrion-derived SO BH4 
oxidation, leading to eNOS uncoupling.  (Crabtree et al. 2008; Perkins et al. 2012).   
Finally, and increased BH2/BH4 ratio causes BH2 to become the eNOS cofactor to 
stimulate eNOS uncoupling, which is a main producer of SO (Alp and Channon 2004).  It 
is well known that BH2 and BH4 bind to the oxygenase domain of eNOS with equal 
affinity, so when the BH2/BH4 ratio is increased, BH2 can easily displace BH4 to become 
the eNOS cofactor (Chen et al. 2010) (See Figure 2). Another likely mechanism for the 
continued oxidation of BH4 is caused by an interaction with peroxynitrite, which is 
generated from the interaction between NO and SO to produce peroxynitrite anion 
(ONOO-).  This leads to a perpetual cycle when superoxide in the endothelium scavenges 
the NO to produce ONOO-, which will then oxidize BH4 to BH2. The BH2:BH4 ratio will 
increase and cause eNOS uncoupling, and this further produces SO to quench the NO and 
continues to promote vascular oxidative stress (Alp and Channon 2004).  
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Figure 2. BH4/BH2 ratio controls NO and SO generation from eNOS. 
The augmentation of BH4 via supplementation or synthesis will increase the 
production of NO by promoting eNOS coupling.  By contrast, low BH4 levels or an 
increase in BH2 will promote eNOS uncoupling and lead to an increase in SO 
generation. Adapted from Vasquez-Vivar et al. 2002. 
 
BH4 is synthesized from three pathways: de novo biosynthesis pathway, salvage 
pathway and de novo regeneration pathway.  In the de novo biosynthesis pathway, BH4 is 
synthesized from guanosine triphosphate (GTP) by GTP cyclohydrolase I, which is the 
rate limiting step in this pathway, to d-erythro-7,8-dihydroneopterin triphosphate, which 
is then converted to 6-pyruvoyl-tetrahydropterin by 6-pyruvoyl-tetrahydropterin synthase.  
Lastly is it converted to BH4 by sepiapterin reductase through NADPH-dependent 
reductions.  In the salvage pathway, non-enzymatic sepiapterin is converted to BH2 by 
sepiapterin reductase, and BH2 is then reduced to BH4 by dihydrofolate reductase 
(Seungkyoung et al. 2006). 
 
 
BH4 and BH2 
  
It has been well established that a decrease in endothelial-derived NO and an 
increase in SO are the key factors leading to vascular endothelial dysfunction.  There are 
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several factors that contribute to the loss of NO bioavailability during endothelial 
dysfunction, including reduced NO synthesis and NO scavenging by reactive oxygen 
species, such as SO, which increases the oxidative stress by forming ONOO- (Alp and 
Channon 2004).  Current research has shown that the eNOS cofactors, BH4 and BH2, are 
intertwined with the levels of NO and SO released from the endothelium due to eNOS 
coupling and uncoupling, respectively.  Vasquez-Vivar et al. (2002) have produced 
research showing that the presence or absence of eNOS cofactor BH4 critically controls 
the release of NO and SO, respectively.  Thus, supplementation with BH4 will prevent the 
accumulation of reactive oxygen species and promote the production of NO.  On the 
other hand, supplementation with BH2, the oxidized form of BH4, will promote the 
production of SO.  Lastly, they claim that elevating BH4 levels via supplementation is 
crucial to saturate eNOS that is deficient in BH4 or to compete with BH2 for the eNOS 
binding site to decrease SO formation and increase NO generation (Vasquez-Vivar et al. 
2002). 
A study by Crabtree et al. (2008) showed the clinical relevance of the BH4/BH2 
ratio on endothelial function by assessing the flow-mediated vasodilatation (FMD) in the 
brachial artery.  Their results showed that there was a significant positive correlation 
between FMD and BH4, a negative relationship between FMD and BH2, and 
subsequently a significant positive relationship between FMD and the BH4/BH2 ratio.  
Also, their results indicated that plasma BH2 levels increased, whereas levels of BH4 
remained unchanged, in association with the increment number of various coronary risks 
factors that the patients in the study had.  
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 Furthermore, our lab has also conducted research in the past using BH4 and BH2 
to attenuate or exacerbate endothelial dysfunction caused by a true I/R injury in femoral 
and myocardial I/R models (Chen et al. 2010).  The results from the Chen et al. study 
(2010) showed BH4 increased NO release from the endothelium in a dose-dependent 
manner by promoting eNOS coupling, and H2O2, the marker for oxidative stress, was 
significantly decreased and this data correlates with improved post-reperfused cardiac 
function.  By contrast, BH2 lead to decreased NO bioavailability, which was due BH2 
promoting eNOS uncoupling to produce SO instead of NO, further quenching NO due to 
the formation of ONOO-.  This data correlated with compromised post-reperfused cardiac 
function (Chen et al. 2010) and suggested that by administering BH4 at the start of 
reperfusion to maintain eNOS coupling would help attenuate the oxidative stress that 
leads to vascular endothelial dysfunction.  It is our hope that by administering BH4 and 
BH2 after ESWL treatment we will see similar results in NO and H2O2 release in the 
kidney vasculature as was seen in the hind limb I/R model, and this could lead us on the 
right tract to be able to attenuate the vascular damage caused by ESWL treatment for 
kidney stones. 
 Previous studies by this lab using this ESWL model have investigated the effects 
of ESWL on NO and H2O2 levels and experimented with regulation from protein kinase 
C epsilon (PKC-ε), which is expressed in the endothelium and positively regulates eNOS 
activity by phosphorylation (Iames et al. 2011).  Specifically, last year Iames et al. (2011) 
explored the effects of PKC-ε regulation through PKC-ε activator and inhibitor peptides 
on ESWL-induced oxidative stress.  The PKC-ε activator and inhibitor peptides regulate 
eNOS by either facilitating or inhibiting the translocation of PKC-ε to the cell membrane, 
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respectively, which promotes or inhibits PKC-ε phosphorylation of the cell member 
substrates, such as eNOS (Iames et al. 2011; Zhang et al. 2005).  The study results 
indicated that PKC-ε inhibitor significantly attenuated the ESWL-induced effects on 
H2O2 increase and NO decrease, and the data suggesed that these beneficial effects were 
from the inhibition of uncoupled eNOS activity (Iames et al. 2011).  Furthermore, PKC-ε 
activator was similar to ESWL-saline controls that showed increased H2O2 and decreased 
NO release compared to no-ESWL controls.  The Iames et al. (2011) study suggested that 
inhibiting eNOS uncoupling reduced oxidative stress in ESWL and was consistent with 
the hypothesis in this study. 
In this study, we will again test the effects of ESWL on NO and H2O2 release to 
confirm ESWL-induced oxidative stress.  We will also explore the effects of regulating 
eNOS coupling and uncoupling with the supplementation BH4 and BH2, respectively, on 
levels of NO and H2O2 in an attempt to decrease endothelial dysfunction after ESWL 
treatment. 
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Hypothesis 
 This project will study the effects of ESWL on the levels of H2O2 and NO release 
from vascular endothelium of the left renal vein.  Furthermore, the project will focus on 
the changes in H2O2 and NO release after infusion with BH2 or BH4 to facilitate eNOS 
uncoupling or coupling, respectively under ESWL treatments.   
 
Effects of ESWL on H2O2 and NO Release Compared to Non-ESWL Controls 
The induction of ESWL treatment on saline controls (ESWL + saline) will 
decrease NO release and increase H2O2 release compared to saline controls that did not 
receive ESWL treatment (no-ESWL + saline).  The stress from the acoustic shockwaves 
generated by ESWL will damage the renal endothelium and increase oxidative stress.  
This is turn will stimulate the production of H2O2 and decrease NO bioavailability.  The 
no-ESWL control group will provide a baseline level of blood H2O2 or NO release for 
which the other experimental groups can compare.  
 
Effects of BH4 on H2O2 and NO Release 
We hypothesized that the infusion of BH4 post-ESWL treatment (ESWL + BH4) 
would cause less of a decrease in NO bioavailability compared to ESWL + saline 
controls.  Furthermore, infusion of BH4 post-ESWL will decrease the release of H2O2 
compared to ESWL + saline controls.  This hypothesis suggests that administration of 
BH4, the cofactor for promoting eNOS coupling, will allow eNOS to increase NO release 
while decreasing SO production and subsequent H2O2 release.  
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Effects of BH2 on H2O2 and NO Release 
We hypothesized that the infusion of BH2 post-ESWL (ESWL + BH2) would 
decrease NO release and increase H2O2 release compared to ESWL + saline control or 
EWSL + BH4.  Administration of BH2, the cofactor for eNOS uncoupling, is assumed to 
have the opposite effects of BH4, by promoting more eNOS uncoupling. This in turn 
would decrease NO release while inducing eNOS SO production and subsequent H2O2 
release.   
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Methods 
 
 
Measurement of NO and H2O2 Release from Left Rat Renal Vein 
 
 Each experimental rat was anesthetized with an initial induction dose of sodium 
pentobarbital (60mg/kg) with an intraperitoneal (i.p.) injection.  A maintenance dose 
(30mg/kg) of sodium pentobarbital was given via i.p. injection at approximately 45-
minute intervals unless otherwise required.  The rat was also injected i.p. with 1 milliliter 
(mL) of sodium heparin (1000 USP units/mL) to prevent blood clotting.  The rat’s back 
was then covered with Sonotech Litho Clear acoustic transmission gel (Magnaflux, 
Bllingham, WA) to ensure constant contact of the animal with the lithotripter via a gel 
medium.  The rat was placed on a wooden operating sheet, and it’s left kidney was 
aligned within the range of the lithotripter’s focal point.  Next, the external jugular vein 
was exposed and a 24-gauge catheter was inserted for drug or saline infusion after the 
ESWL treatment was finished.  A mid-line laparotomy was performed on the animal to 
isolate the left renal vein.  Once exposed, the left renal vein was catherized using a 22-
gauge angio-catheter (Figure 3). 
 A NO or H2O2 microsensor (100µm diameter) was inserted through the renal vein 
catheter and then connected to the Apollo 4000 Free Radical Analyzer (World Precision 
Instruments (WPI), Inc. Sarasota, FL), which provides a real-time measurement tracing 
of NO or H2O2 release through an electrical picoamp (pA) response.  The microsensor 
was supported by gauze and positioned in direct opposition of the blood flow of the left 
renal vein.  Only the left renal vein can be exposed and isolated for catherization, so only 
one microsensor can be used per experiment, hence only NO or H2O2 can be measured at 
one time.   
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Once the sensor was inserted into the left renal vein via the 22-gauge catheter, a 
period of baseline measurements were taken.  The tracing was recorded until the baseline 
was considered stable, which is when a decrease of 300 picoamps (pAs) every 300 
seconds is reached.  The final baseline recording served as a “zero” recording and all 
measurements taken post-ESWL would be expressed as relative difference compared to 
the final baseline measurement as in previous studies (Iames et al. 2011; Chen et al. 
2010). 
After a stable baseline was established, ESWL treatment was initiated and 1000 
shocks were delivered in two different frequency periods.  The first 500 shocks was 
delivered in a lower frequency period of 60 beats per minute, and the last 500 shocks was 
delivered in a higher frequency period of 120 beats per minute.  The entire ESWL 
treatment was given at an intensity level of 13 (16kV), which is the highest intensity 
setting on this lithotripter, and the shockwave treatment lasted approximately 13 minutes.  
For the non-ESWL controls, ESWL treatment was never induced and there was a 13-
minute waiting period of pseudo-ESWL.  This protocol was adapted from Weber et al. 
(1992), and it was later modified by our research group in Iames et al. (2011) and Chen et 
al. (2010). 
 Immediately after the cessation of ESWL treatment or pseudo-ESWL, 0.5 mL of 
saline or saline + drug was infused through the jugular vein canulation, and then another 
0.5 mL of saline was infused as a flush.  In ESWL + drug experiments, the appropriate 
dosage of either BH2 (mol. wt. 239.23)(Cayman Chemicals) or BH4 (mol. wt. 
314.2)(Cayman Chemicals) was infused with 0.5 mL of saline.  Previous studies have 
established the appropriate dosage for each drug, and BH2 is given at 2.0 mg/kg (100 µM 
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approximately in blood) and BH4 is given at 6.5 mg/kg (250 µM approximately in blood).  
Recordings were taken in pA from the free radical analyzer at the beginning and end of 
ESWL treatment and then in five-minute intervals for 30 minutes post-ESWL treatment 
as previously described (Iames et al. 2011). 
 
Animal Model 
 The Institutional Animal Care and Use of Laboratory Animals Committee of the 
Philadelphia College of Osteopathic Medicine approved the experimental protocol 
preformed in this study.  The animals used in all experiments were male Sprague-Dawley 
rats (275-325 grams) (Ace Animals, Boyertown, PA). 
 
Experimental Apparatus 
 A Dornier Epos Ultra HE (high-energy) lithotripter (Dornier MedTech, 
Kennesaw, GA) was used to induce the ESWL shockwave treatment.  During each 
experiment, the free radical tracing was recorded by the Apollo 4000 Free Radical 
Analyzer (WPI, Inc.)  A NO or H2O2 microsensor (100µm) (WPI, Inc.) was connected to 
the free radial analyzer which was linked to a built-in computer, which recorded the NO 
or H2O2 tracing, respectively. 
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Figure 3. The rat is placed on a board that maintains the left kidney within the focal 
point of the shock wave transmitter on the lithotripter’s mechanical arm. The 
microsensor is inserted into the left renal vein and supported by gauze in direct 
opposition to the renal vein blood flow. 
 
Microsensor Calibration 
 All NO and H2O2 microsensors were calibrated prior to each experiment to 
determine their sensitivity.  The microsensor was calibrated in order to calculate a 
standard calibration curve, which gave a precise and consistent measurement to translate 
data across all experiments.  The tracings were recorded on the free radical analyzer from 
the electrical response in pA and were translated into molar concentration in vivo using 
the standard curve.  The standard curve was created by a stepwise dose-response of the 
NO or H2O2 microsensor using an appropriate standard solution depending on the type of 
sensor being calibrated. 
 There are no microsensors for SO, so H2O2 will be monitored as an indirect 
product of SO.  SOD catalyzes the reaction between SO and hydrogen ions, which results 
in H2O2, and thus H2O2 indirectly reflects the concentration of SO in the cells/blood.  To 
calibrate the H2O2 microsensor, the reference tip of the sensor was submerged in 10 mL 
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of phosphate buffered saline (PBS 0.01M) until the trace recorded a stable baseline.  The 
standard 1.0 mM H2O2 solution was prepared in deionized water, and aliquots of 2.5 µL, 
5.0 µL, 10.0 µL, and 20.0 µL (250-2,000 nM) were added stepwise to generate the 
standard calibration curve for that H2O2 microsensor. 
 To calibrate the NO microsensors, the reference tip of the sensor was submerged 
in 10 mL of 0.2 M copper sulfate (CuSO4) until a stable baseline was registered.  The 
standard NO solution was prepared, which consisted of 50 mL aqueous solution with 
solutes of 1mg ethylene diamine tetraacetic acid and 1.06 mg of S-nitroso-N-acetyl-1,1-
penicillamine (SNAP).  Aliquots of 1.0µL, 5.0µL, 10.0µL, and 20.0µL of SNAP (10-200 
nM) were added stepwise in order to record the NO standard calibration curve. 
 
Table 1. Sample Calibration Curve for NO Microsensor. 
 
NO (nM) Picoamp (pA) response 
0 0 
6 530.02 
30 1755.55 
60 3154.86 
120 4550.83 
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Figure 4. Sample Calibration Curve for NO Microsensor. 
 
Experimental Groups 
 Each experimental group was exposed to the same number, intensity and 
frequency of ESWL shockwaves, except the non-ESWL group, which consisted of a 13- 
minute wait period of pseudo-ESWL, which is the time it takes to complete ESWL 
treatment. 
 
Table 2.  Experimental Groups. 
 
Group Nitric Oxide (NO) Hydrogen Peroxide (H2O2) 
Non-ESWL Control  
(No Drug) 
n=6 n=5 
ESWL + Saline Control 
(1mL 0.9% Saline) 
n=5 n=5 
ESWL + BH4 
(6.5 mg/kg BH4) (250µM) 
n=5 n=5 
ESWL + BH2 
(2.0 mg/kg BH2) (100µM) 
n=5 n=5 
 
 
 
 
 
NO (nM) 
Picoamp(pA) 
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Statistical Analysis 
 All data in the text and figures were presented as means ±SEM.  The data for each 
recorded time-point were compared using the analysis of variance (ANOVA) using the 
post hoc analysis with the Bonferroni/Dunn.  Probability values of less than 0.05 (i.e., p< 
0.05) were considered to be statistically significant. 
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Results 
The two graphs in this section are measured as relative changes from baseline, 
and baseline is considered to be “zero”.  When an experimental group shows a decrease 
or increase of NO or H2O2 release, it is signified as a change from zero to a negative or 
positive number, respectively. 
 
 
 
Figure 5.  Effects of BH4 and BH2 on Real-time blood NO release after ESWL. 
This graph shows change in NO release in renal blood post-ESWL relative to 
baseline.  ESWL significantly reduced NO release (by 196.90 nM from baseline) 
compared to no-ESWL (**p≤0.01) from 5-30 minutes post-ESWL.  ESWL + BH4 
group is similar to no-ESWL control.  ESWL + BH4 significantly attenuates 
decreased NO levels (5-30 min post-ESWL) compared to ESWL + saline groups 
(**p≤0.01). ESWL + BH2 group is similar to ESWL+ saline group and reduced NO 
release by 242 nM from baseline.  There was significant difference between ESWL + 
BH4 compared to ESWL + BH2 or ESWL + saline from 5-30 minutes. (**p≤0.01, 
compared to ESWL + saline) (#p≤0.05, ##p≤0.01, compared to ESWL+BH2) 
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Effects of BH4 and BH2 on Real-time Blood NO release after ESWL 
 The results in Figure 5 show the relative changes of NO release after ESWL 
treatment in the no-ESWL saline control, ESWL-treated saline control, ESWL + BH4 
treated group and ESWL + BH2 treated group.  The baseline for NO levels for each group 
is set at 0 nM and every other time point illustrates either an increase or decrease in NO 
release.  In this graph, the ESWL + saline control group shows a sustained and 
progressive decrease in NO release over 30 minutes post-ESWL.  The ESWL + saline 
control group showed an average decrease of 196.90 nM NO release over the 30 minute 
time period compared to the no-ESWL control group, which only had a decrease in NO 
release of 42.94 nM.  The infusion of BH2 post-ESWL treatment showed a similar trend 
in decreased NO release as the ESWL + saline control group, with an averaged decreased 
NO release of 242.34 nM over the 30 minute time period.  On the other hand, the infusion 
of BH4 post-ESWL follows a similar trend to the no-ESWL saline control group by 
attenuating the decrease of NO release.  The ESWL + BH4 treated group showed an 
averaged decrease in NO release of only 24.53 nM, which was significantly higher 
compared to the ESWL-saline or ESWL + BH2 group.  Moreover, the ESWL + BH4 
group was similar to the no-ESWL control group in renal blood NO release throughout 
the experimental protocol. 
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Figure 6. Effects of BH4 and BH2 on Real-time blood H2O2 release after ESWL.  
This graph shows change in H2O2 release in renal blood post-ESWL relative to 
baseline. ESWL significantly increased H2O2 release by 1µM compared to no-
ESWL from 5-30 minutes post-ESWL.  The ESWL-induced H2O2 levels were 
significantly attenuated by BH4 compared to the saline control group from 10-30 
minutes post-ESWL. There was no significant difference in H2O2 levels for ESWL + 
BH2 compared to ESWL + saline. There was significant difference of ESWL + BH4 
((#p≤0.05) compared to ESWL + BH2 from 15-30 minutes.  (*p≤0.05, **p≤0.01, 
compared to ESWL + saline) (#p≤0.05, ##p≤0.01, compared to ESWL + BH2) 
 
Effects of BH4 and BH2 on Real-time Blood H2O2 release after ESWL 
 The results in Figure 6 show the relative changes of H2O2 release in the no-ESWL 
saline control, ESWL-treated saline control, ESWL + BH4 treated group and ESWL + 
BH2 treated group.  The baseline for H2O2 levels for each group is set at 0 µM and every 
other time point illustrates either an increase or decrease in H2O2 release.  In this graph, 
the ESWL + saline control group shows a sustained and progressive increase in H2O2 
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release compared to the no-ESWL saline control group.  The ESWL + saline control 
group had increased the level of H2O2 release by 1.02 nM to the no-ESWL saline controls 
over the 30 minute time period.  The infusion of BH2 post-ESWL shows a similar trend 
to the ESWL + saline control group, with an increased level of H2O2 release (0.75 nM) 
compared to the no-ESWL control group.  Infusion of BH4 post-ESWL did significantly 
attenuate the ESWL-induced H2O2 release from the 10-30 minute time points by 0.98µM; 
this is a decrease of 0.56 µM compared to the ESWL + saline control group.  The 
infusion of BH4 did not decrease H2O2 release to the level of no-ESWL controls, so BH4 
infusion did not totally negate the effect of ESWL on H2O2.  However, the ESWL + BH4 
group was not significantly different from the no-ESWL control group. 
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Discussion 
 
Summary of Major Findings 
 The major findings of this study conclude the results found in the comparison of 
the no-ESWL control group to the ESWL-saline control group and also between the 
ESWL-saline control group and the ESWL+ BH4 and ESWL+ BH2 treated groups.  
Compared to the no-ESWL control group, the ESWL-saline control group showed 
significantly decreased blood NO release and significantly increased blood H2O2 release 
after ESWL therapy.   This supports our first hypothesis that ESWL treatment causes 
oxidative stress, such as increased oxidative stress (i.e. H2O2) and also causes reduced 
NO bioavailability.  The results of the ESWL+BH4 treated group are similar to the no-
ESWL control group, which may be due to promoting eNOS coupling.  Lastly, the 
ESWL +BH2 treated group is similar to the ESWL-saline control group and further 
confirms our hypothesis that BH4 would attenuate ESWL-induced oxidative stress and 
decreased NO bioavailability.  However, we hypothesized that BH2 would exacerbate 
ESWL-induced oxidative stress and it only remained similar to ESWL + saline control.  
We speculate that this maybe due to high levels of BH2 already generated by ESWL that 
produced saturation of eNOS binding conditions. 
 
Effect of ESWL Treatment of Normal Renal Vein NO and H2O2 Release 
 The results from ESWL on NO and H2O2 blood levels confirmed the increased 
oxidative stress on the kidney vasculature after ESWL treatment.  This study showed that 
ESWL results in increased oxygen free radicals, such as SO, which is then further 
converted to H2O2 by superoxide dismutase.  Levels of H2O2 release were significantly 
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increased during the entire 30-mintue time period post-ESWL compared to no-ESWL 
saline control group, and NO levels were significantly decreased compared to the same 
group during the 30-mintues post-ESWL.  Even taking into account the new protocols for 
ESWL to limit the damage to the kidney, oxidative stress to the kidney vasculature may 
still occur after treatment.  These changes in NO and H2O2 release levels are 
characteristic of an I/R injury that leads to vascular endothelial dysfunction.  Although 
ESWL produces more of a pseudo-I/R injury because the kidney does not undergo 
complete loss of blood perfusion during the treatment, the results of ESWL on NO and 
H2O2 levels are very similar to a true I/R injury.  As seen in a study by Parker et al. in 
2012 that induced a true I/R injury using femoral artery clamping and subsequent release 
in a rat model, blood levels of NO and H2O2 decreased and increased, respectively, 
compared to the sham limb that did not undergo femoral artery clamping (Parker et al. 
2012).  The increased oxidative stress and reduced NO bioavailability caused by ESWL 
treatment are characteristic of endothelial dysfunction, which characterizes many 
vascular disease states, such as diabetes, atherosclerosis and mainly in the kidney, 
hypertension (Channon 2004).  A 19 year follow up study by Krambeck et al. in 2006 
showed a correlation between patients treated with ESWL for renal and proximal ureteral 
stones and the development of diabetes mellitus and hypertension.  The development of 
diabetes mellitus was related to the number of shockwaves delivered and the intensity of 
the ESWL treatment.  Furthermore, cases of hypertension were significantly higher in 
patients treated with ESWL compared to that in patients treated conservatively with 
stones, and they suggest that damage to the renal parenchyma and vasculature contributes 
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to the development of hypertension in these patients.  Lastly, the study shows that this 
effect was exacerbated in patients with bilateral ESWL treatments (Krambeck et al. 2006) 
 
Effect of BH4 on NO and H2O2 release levels after ESWL treatment 
 This study shows that supplementation with BH4 can attenuate the oxidative stress 
that is caused by ESWL treatment.  The results conclude that supplementation with BH4 
was able to attenuate the reduced NO bioavailability caused by ESWL immediately after 
5 mins post-ESWL and lasts for 30 minutes following treatment.  Furthermore, the results 
show that giving BH4 after ESWL leads to normal basal levels of NO that are similar to 
no-ESWL treatment.  Moreover, after 5 minutes post-ESWL, the NO release level starts 
to increase compared to the no-ESWL control.  This shows that supplementation with 
BH4 increases the BH4 to BH2 cofactor ratio to favor eNOS coupling activity to produce 
more NO, and it gives protection against reduced NO bioavailability caused by ESWL.   
 This study also shows that giving BH4 will reduce H2O2 levels after 10 minutes 
post-ESWL.  Again, the BH4 treated group is similar to the no-ESWL control in terms of 
significantly decreased H2O2 release levels during the 30 minute post-ESWL time line 
compared to ESWL + saline group.  However, the no-ESWL group displayed the greatest 
drop in H2O2 release among the four study groups.  Two possible causes of this could be 
that 1) eNOS was saturated with BH4 and/or 2) there was too much SO produced during 
the ESWL treatment that it was quenching the NO produced by coupled eNOS to produce 
ONOO- anion that was causing some residual oxidative stress, hence more elevated H2O2 
levels compared to no-ESWL.  These results show that supplementation with BH4 after 
ESWL treatment is entirely protective in terms of attenuating the decreased NO caused 
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by ESWL, but it is only partially protective in decreasing the H2O2 release to the level of 
the no-ESWL control group. 
 
Effect of BH2 on NO and H2O2 release levels after ESWL treatment 
 This study shows that supplementation with BH2 can maintain and further add to 
the oxidative stress that is caused by ESWL treatment.  The data shows that the BH2-
treated group is similar to the ESWL-saline control group.  In terms of NO and H2O2 
release post-ESWL, the results conclude that supplementation with BH2 decreased NO 
release levels compared to the BH4 or no-ESWL groups and suggests that BH2 
maintained increased oxidative stress and decreased NO bioavailability due to ESWL-
induced eNOS uncoupling.  Because ESWL leads to oxidative stress, the oxidative stress 
is known to oxidize BH4 to BH2, which then increases the BH2 to BH4 cofactor ratio and 
BH2 becomes the eNOS cofactor.  In this situation, eNOS uncoupling activity is 
promoted and more SO is produced to quench NO bioavailability.  
 This study also shows that supplementation with BH2 is similar to the ESWL-
saline control group in terms of H2O2 release.  On the other hand, the BH2 treated group 
did not show as drastic an increase in H2O2 as the ESWL-saline group as we had 
expected.  Two possible causes of this could be that 1) the dosage of BH2 is not high 
enough, which could be examined in future studies and/or 2) that the eNOS was already 
saturated with the BH2 cofactor and that it couldn’t produce more H2O2. 
Limitations 
 One of the main limitations to this study was the rat models subjected to the 
ESWL procedure did not have kidney stones, unlike in true clinical settings where the 
patients receiving the ESWL treatment do have kidney stones.  Therefore, we were 
   35 	  
unable to access how the presence of a kidney stone would affect the oxidative stress 
cause by ESWL.  It could be speculated that a kidney stone could absorb some of the 
damaging shock waves and therefore, may be less invasive than in the non-kidney stone 
rat model that we used in this study. 
  
Future Studies 
 One of the reasons that BH4 has limited utility on H2O2 in the setting of an I/R 
injury may be that the higher doses are not effective due to the oxygenase domain of 
eNOS being at saturated conditions with BH4.  A promising alternative to overcome this 
situation is to enhance eNOS activity, using PKC-ε activator, along with BH4 to promote 
eNOS coupling to increase NO release during reperfusion (Perkins et al. 2012).  
Furthermore, it has been shown in a hind limb I/R model that PKC-ε inhibitor 
significantly reduced H2O2 release, which suggests that the attenuation of eNOS activity 
is associated with reduced oxidative stress (Teng et al. 2008).  The major findings of a 
study using a hind limb I/R model with supplementation of PKC-ε activator/inhibitor and 
BH4/BH2 are significant to this ESWL model and should be implemented into the future 
studies of this project.  The findings of the hind limb I/R model were that treatment with 
PKC-ε activator + BH4 was associated with a significant increase in NO release and 
decrease in H2O2 release, which supports the hypothesis that promoting eNOS coupling 
(i.e. BH4) combined with an eNOS activity enhancer (i.e. PKC-ε activator) would 
attenuate oxidative stress from an I/R injury (Perkins et al. 2012).  Furthermore, groups 
treated with PKC-ε activator + BH2 were associated with increased H2O2 and decreased 
NO release, and were shown to exacerbate the oxidative stress.  Lastly, all PKC-ε 
inhibitor groups treated with either BH4 or BH2 decreased H2O2 release and increased NO 
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release in hind limb I/R.  This is because PKC-ε inhibitor decreased eNOS activity in its 
uncoupled state, therefore H2O2 release is decreased and also, it reduces the quenching of 
NO by SO, which subsequently increases NO bioavailability (Perkins et al. 2012).  The 
future research of this project will be directed towards investigating the effects of 
treatment with all combinations of PKC-ε activator/inhibitor and BH4/BH2 to attenuate 
the ESWL-induced oxidative stress in this model.  Furthermore, plasma samples were 
collected from post-ESWL-treated and non-ESWL treated rats, and in a future study 
these samples can be evaluated to determine the concentration ratio of BH4:BH2 in 
ESWL-treated and non-treated plasma. 
  
Significance of Findings 
 Until the technology improves or another method for targeting kidney stones is 
developed, treatment for the damage caused by ESWL treatment must focus on 
improving the technique of ESWL delivery or pharmacological invention.  Although 
there is new research on improving ESWL delivery protocols to minimize the damage, 
there is still a lack of research conducted on the ESWL-induced oxidative stress that leads 
to vascular endothelial disease states, such as acute to chronic hypertension.  This study 
confirms that even under the safer ESWL procedures, the blood levels of H2O2 and NO 
release indicate increased oxidative stress and reduced NO bioavailability post-ESWL 
treatment, which are both major characteristics of endothelial dysfunction.   Our research 
has also found that eNOS is the principal target responsible for oxidative stress after 
lithotripsy as BH4 is oxidized to BH2.  The data from this study suggests that the 
beneficial effects of BH4, such as increased NO release, may be due to the increased BH4 
to BH2 ratio, which promotes coupled eNOS.  Furthermore, our data suggests that 
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supplementation of BH2 reverses this ratio in favor of BH2 to promote uncoupled eNOS 
with the further production of SO, which is the primary source of oxidative stress post-
ESWL.  In conclusion, this study suggests that supplementation of BH4 after ESWL 
treatment could increase NO bioavailability and reduce oxidative stress to attenuate 
endothelial dysfunction to the renal vasculature to avoid the development of hypertension 
clinically. 
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